No statistically significant differences were found in the cytokine profile among those patients in normally progressing pregnancy or in threatened preterm labour. No suitability of progesterone treatment in threatened preterm labour was observed.
Objectives: The purpose of our study was to analyze the cytokine profile in threatened miscarriage, defined as vaginal bleeding and uterine contractions with a closed cervix, occurring before the end of week 22 of gestation. Materials and methods: The study included 46 women hospitalized at the Obstetrics & Gynecology Clinical Hospital. Group 1 comprised of 14 patients diagnosed with threatened miscarriage, prior to pharmacological treatment. Group 2 comprised of 20 patients with identical diagnoses. The patients were administered drotaverine hydrochloride (3x40 mg) and progesterone transvaginally (2x100 mg). Group 3 constituted the control group, comprising of 12 women in normally-progressing pregnancy, before completing week 22 of gestation. Results: The present analysis was focused on the cytokine profile of the women included in the study, but no considerable changes in cytokine concentration were observed. The results of determining the IFN-γ and TNF-α, IL-2, IL-4, IL-6, IL-10, IL-17, and CRP levels in all groups proved to be comparable; moreover, no considerable differences were found in the CRP level or vaginal flora. Conclusions: The present authors failed to identify any significant differences in the cytokine profile between patients in normally-progressing pregnancy and patients diagnosed with threatened miscarriage. This finding needs to be confirmed in a study in a larger group of pregnant women.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.